3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
2
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Prostatic Neoplasms
1
Pancreatic cancer, adult
1
Ovarian Germ Cell Cancer
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Lung Neoplasms
1
Hip Fractures
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Paclitaxel
328
Carboplatin
323
Bevacizumab
171
Gemcitabine
106
liposomal doxorubicin
104
pembrolizumab
101
Cyclophosphamide
96
Topotecan
94
olaparib
92
Cisplatin
92
niraparib
69
Docetaxel
57
Taxes
52
Doxorubicin
51
Drug Therapy
45
fludarabine
40
Filgrastim
39
Nivolumab
37
Magnetic Resonance Spectroscopy
34
Surveys and Questionnaires
33
Specimen Handling
33
Etoposide
32
Hyperthermic Intraperitoneal Chemotherapy
31
Blood Specimen Collection
29
Immunoglobulin G
27
Disulfides
27
Peripheral Blood Stem Cell Transplantation
26
Cytoreduction Surgical Procedures
25
Albumin-Bound Paclitaxel
25
durvalumab
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Hematologic Tests
×
Gynecologic
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled
NCT06329323
2024-03-26
SUMMER
Imperial College London
Not yet recruiting
24 enrolled